Author:

Keywords:

tetralogy of fallot, pulmonary homograft, homograft degeneration, allograft, ventricular outflow tract, congenital heart-disease, anti-hla antibodies, aortic-valve, cryopreserved homografts, immune-response, pulmonary position, allograft conduit, follow-up, reconstruction, Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, tetralogy of Fallot, OUTFLOW TRACT RECONSTRUCTION, ALLOGRAFT HEART-VALVES, ANTI-HLA ANTIBODIES, CRYOPRESERVED HOMOGRAFTS, PULMONARY POSITION, IMMUNE-RESPONSE, AORTIC VALVES, IMPLANTATION, CONDUITS, DYSFUNCTION, Adolescent, Adult, Female, Graft Survival, Humans, Male, Middle Aged, Regression Analysis, Reoperation, Risk Factors, Tetralogy of Fallot, Time Factors, Transplantation, Homologous, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, Cardiovascular System & Hematology, 3201 Cardiovascular medicine and haematology, 3202 Clinical sciences

Abstract:

Aims Homografts are frequently implanted in patients with tetralogy of Fallot (TOF). However, the lifespan of homografts is shorter than that of graft recipients, thus making surgical re-intervention unavoidable. Therefore, to determine variables that could influence their survival, we retrospectively studied the survival pattern of homografts used to treat TOF.